NCT07006246View on ClinicalTrials.gov

Utilizing Private Pharmacies to Initiate High-risk Young Individuals on PrEP in South Africa

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

1,900

Participants

Timeline

Start Date

May 19, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
HIV Infection
Interventions
DRUG

Tenofovir disoproxil fumarate + lamivudine/emtricitabine (TDF+3TC /FTC)

Tenofovir disoproxil fumarate + emtricitabine/ lamivudine Dosage Formulation: 300 mg / 200 mg (300mg) fixed dose combination tablet Route of Administration: Oral Dosing Instructions: 1 tablet (300/200/ TDF/FTC) daily or (300/300/TDF/3TC) daily

Trial Locations (1)

2193

Ezintsha, a division of Wits Health Consortium, Johannesburg

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Professor Francois Venter

OTHER